Podcasts about chan zuckerberg biohub

“I wish someone had told me when I was starting my PhD to sit down and say, ‘what do I want out of this?' and [then] write it down. Because, unlike the UK, where PhDs are three years and time bound, in Canada, they are neither time bound nor three years. And so you can meander." In this episode of The Biotech Startups Podcast, Rabia Khan, founder and CEO of Serna Bio, joins host Jon Chee to reflect on her unconventional journey through academia, business, and biotech innovation. Rabia shares how her curiosity, resilience, and embracing uncertainty shaped her journey through a PhD in genetics and an MBA. She discusses the emotional challenges of working with animal models, the benefits and limits of business school for scientists, and personal struggles, including her father's illness. She recounts early setbacks, like rejected consulting jobs, and how a cold email landed her at Meta (now part of Chan Zuckerberg Biohub). Rabia emphasizes “manufacturing serendipity,” differences between founder and employee mindsets, and lessons from her work at BenevolentAI, highlighting the importance of cross-disciplinary communication and challenging industry norms

In this episode, Hannah McGillivray and Prottusha Sarkar sit down with Amanda Murphy, the Chief Operations Officer of the Chan Zuckerberg Biohub in Chicago, and her right-hand woman, the Lab Operations Manager, Juhi Naik. They discuss the mandate of the Chan Zuckerberg Biohubs, the operations that go into running a research institute, as well as career advice for those interested in healthcare.

This special episode features the most recent edition of Weinberg College's faculty speaker series “Conversation with the Dean.” This event series is designed to deliver insights into cutting-edge research and teaching from faculty experts around the College. The events are offered live to Weinberg College Leadership Society donors with a real-time Q&A. In this conversation, Professor of Chemistry Shana Kelley and Dean Adrian Randolph discuss creating new tools to diagnose and treat diseases, the importance of interdisciplinary and translational research at Weinberg College, and the Chan Zuckerberg Biohub: a new and cutting edge collaboration between Northwestern, UChicago, and the University of Illinois Urbana-Champaign. Weinberg College Leadership Giving Society: https://giving.northwestern.edu/s/1479/282-giving/21/interior3.aspx?pgid=7407&gid=282   Explore more "Conversations with the Dean:" https://weinberg.northwestern.edu/after-graduation/for-alumni/conversations-with-the-dean/shana-kelley.html

Professor Stephen Quake's research has helped countless patients avoid the pain and suffering that can come with invasive diagnostic testing. Russ and Stephen discuss his work to develop a number of noninvasive blood tests to help detect preterm births, genetic disorders like Down Syndrome, cancer, and organ transplant rejection. It's an episode that reminds us of the power of good science. We hope you'll take another listen and enjoy.Links:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads or Twitter/XConnect with School of Engineering >>> Twitter/XChapters:(00:00:00) IntroductionHost Russ Altman introduces the episode featuring Dr. Stephen Quake, highlighting his contributions to non-invasive blood tests. (00:00:46) Understanding DNA in DiagnosticsIntroduction to the revelation of detecting DNA in the bloodstream, shedding light on various bodily processes.(00:02:24) The Beginning of Dr. Quake's work with Cell Free DNADr. Quake tells the story of his journey into research with cell free DNA beginning with searching for a less risky alternative to an amniocentesis(00:05:11) Impact on Prenatal TestingThe transformation in prenatal diagnostics, replacing invasive tests  & understanding the detection capabilities for prenatal genetic disorders like using cell-free DNA.(00:06:39) Transplant Rejection MonitoringThe discovery of cell free DNA & it's use in heart & lung transplant patients detecting early rejection & the real-life implications of this technology.(00:10:35) Unveiling Infectious AgentsThe detection of infectious agents in blood & the real life applications of this discovery(00:14:52) Advances in Cancer DetectionDiscussion shifts to cancer detection using cell-free DNA, emphasizing the important application of monitoring cancer progression and treatment efficacy. (00:17:18) Predicting Preterm BirthDr. Quake delves into the groundbreaking research predicting preterm births using cell-free RNA and DNA, sharing insights into discoveries indicating preterm birth risks and gestational age predictions and the significance of this.(00:21:42) The Chan Zuckerberg Biohub's MissionThe origins and bold mission of Steve Quake's current work at the Chan Zuckerberg Biohub, to cure, treat, or prevent all human diseases by the end of the century and the feasibility of such an ambitious goal. (00:24:03) Biohub's Research StrategyBiohub's strategy focusing on cell biology and infectious diseases internally, while funding nearly a hundred faculty across diverse areas in Bay Area Universities.(00:26:26) Conclusion  LINKS:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads or Twitter/XConnect with School of Engineering >>> Twitter/X

What does the founder of NextSense, a former Google X director, have to share about the fascinating world of consciousness and the mind-body connection? Jonathan (JB) Berent – an avid practitioner of polyphasic sleep, lucid dreaming enthusiast, and someone deeply interested in altered states of consciousness – takes us through his journey in this enlightening conversation. We unpack his fascination for the interplay between subjective experiences and science, touching upon his spiritual practices and unique sleep routine.Our conversation takes a deep dive into the world of altered states of consciousness, not just from a theoretical standpoint but from Jonathan's own experiences and observations. We also discuss the scientific measurements of these states and how they are clinically oriented around wake and sleep states. From Jonathan's personal experiences, we get an intriguing insight into the concept of flow and how it can bridge the subjective with the objective. We also touch upon the physiological processes that our brain undergoes during these states and how we can observe and comprehend what's happening.In the latter part of our conversation, we examine the role of ego in entrepreneurship and how to mindfully manage it. Using his own experiences, Jonathan illustrates the power of dreams and the delicate balance between ambition and surrender. He also shares how the teachings of Saad Guru, a renowned yogi and visionary, have shaped his journey and helped him make better decisions. So, sit back and join us on this mind-expanding exploration of consciousness, science, and much more.A bit about JB:Jonathan "JB" Berent is a visionary leader who is passionate about exploring human consciousness and unlocking its full potential. As the CEO and Founder of NextSense, he has combined his extensive business experience with cutting-edge scientific research to develop innovative biosensing wearables.Throughout his executive career, JB has managed teams of more than 110 people and overseen budgets of $50M or more at public companies Oracle and Google. However, in 2016, he decided to follow his lifelong passion for exploring the connection between the mind and body and left sales and partnerships to focus on developing brain-sensing technologies at X, the moonshot factory.JB's innovative work has earned him numerous speaking engagements at prestigious universities such as Stanford and UCSF, as well as conferences such as the Chan Zuckerberg BioHub and the Stanford Medicine Big Data Health. In June 2022, he was featured in a long-read cover story in Wired magazine, which highlighted his groundbreaking work in the field of biosensing wearables.JB graduated with Honors from Stanford University with a Philosophy and Religious Studies degree.Support the showTo connect with Kasia @Nourish_Podcast (​​​​Instagram) www.nourishpodcast.co Submit topic/theme/speaker requests

5 January 2023 - “Nobody is doubling the number of cell types,” says Steve Quake, “but what we have now is the full molecular portrait of those cell types”. Quake, who led a decade-long effort to create full organism molecular cell atlases, served for six years as co-President of the Chan Zuckerberg Biohub. He succeeded neuroscientist Cori Bargmann as Head of Science for the Chan Zuckerberg Initiative. Quake came to biology after undergraduate and graduate work in physics and mathematics, and his research group at Stanford has maintained a strong technological and quantitative focus. On this episode of the EMBO podcast, we discussed what a cell type is, Open Science and preprints (Quake and student Michael Swift are currently experimenting with Review Commons – “the jury's still out,” he says), the role of funders, how to start a company, and much more.

This week on the show we chatted with the Dr. Austin Graham (he/him), a postdoctoral fellow in the Gartner lab at UCSF and Chan Zuckerberg Biohub. We discuss Austin's time leading the ROLE Model Program as a graduate student at UT-Austin, the challenges of graduate student-led initiatives, the importance for undergraduate research, the UC Academic Workers strike, & much more! To connect with Austin can follow him on Twitter @austinjgraham and us @MFQCPod. We'll see y'all next time and remember that Black Lives Matter today and everyday. --- Support this podcast: https://anchor.fm/mfqc/support

Manuel Leonetti, group leader in Quantitative Cell Science at the Chan Zuckerberg Biohub in San Francisco, is taking the description of “proteins in the wild” a step further with his project called OpenCell. Through advanced imaging techniques, machine learning, artificial intelligence, data science, and software engineering, OpenCell is able to measure the quantity and track the position of different proteins in human embryonic kidney cells through time and space. So far, Leonetti says, his group has mapped 1,310 different proteins, which might sound like a lot, but this represents just 7% of the human genome. Visit https://opencell.czbiohub.org/ to learn more. --- Send in a voice message: https://anchor.fm/ascb-pathwayspodcast/message

Stephen Quake is the Lee Otterson Professor of Bioengineering & Professor of Applied Physics @ Stanford University & Co-President of the Chan Zuckerberg Biohub. Quake has invented many measurement tools for biology, including new DNA sequencing technologies that have enabled rapid analysis of the human genome and microfluidic automation that allows scientists to efficiently isolate individual cells and decipher their genetic code. Quake is also well known for inventing new diagnostic tools, including the first non-invasive prenatal test for Down syndrome and other aneuploidies. His test is rapidly replacing risky invasive approaches such as amniocentesis, and millions of women each year now benefit from this approach. His innovations have helped to radically accelerate the pace of biology and have made medicine safer by replacing invasive biopsies with simple blood tests.Quake was elected a member of the National Academy of Engineering in 2013 for achievements in single-cell analysis and large-scale integration of microfluidic devices. He has also been elected to the National Academy of Sciences, the Institute of Medicine, the American Physical Society, the American Institute for Medical and Biological Engineering and the American Academy of Arts and Sciences. He is the recipient of numerous international awards, including the Human Frontiers of Science Nakasone Prize, the Jacob Heskel Gabbay Award, the MIT-Lemelson Prize for Innovation, the Raymond and Beverly Sackler International Prize in Biophysics, the NIH Director's Pioneer Award, the American Society of Microbiology's Promega Biotechnology Award, and the Royal Society of Chemistry Publishing's Pioneer of Miniaturization Award. He has founded or co-founded several companies, including Fluidigm, Helicos Biosciences, Verinata Health, Quanticel Pharmaceuticals, Moleculo, Cellular Research, Immumetrix, and Karius.Quake received a B.S. in Physics and M.S. in Mathematics from Stanford University in 1991 and a doctorate in Theoretical Physics from the University of Oxford in 1994 as a Marshall Scholar. He did his postdoctoral work at Stanford in single molecule biophysics with Steven Chu. Quake joined the faculty of the California Institute of Technology at the age of 26, where he rose through the ranks and was ultimately appointed the Thomas and Doris Everhart Professor of Applied Physics and Physics. From 2006 to 2016 he was an Investigator of the Howard Hughes Medical Institute.Thank you for listening!BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.Music: Danger Storm by Kevin MacLeod (link & license)

Dr. Marinka Žitnik is a computer scientist from Harvard, studying applied machine learning with a focus on challenges brought forward by data in science, medicine, and health. A large aspect of her work concerns the use of AI for better use of medications - either by analyzing and predicting side effects in polypharmacy or by potentially discovering new indications of combinations of drugs that are already on the market. Dr. Zitnik joined Harvard as an Assistant Professor in December 2019. Before that, she was a postdoctoral scholar in Computer Science at Stanford University. She was also a member of the Chan Zuckerberg Biohub at Stanford. Some of her methods are used by major biomedical institutions, including Baylor College of Medicine, Karolinska Institute, Stanford Medical School, and Massachusetts General Hospital. In this discussion, she talks about the role of AI in the development of COVID vaccines, the role of AI in drug development, realistic expectations of AI tools we can expect in the next 5 to 10 years, and more.  *** This discussion was part of the discussions recorded for the movie OVERDOSE - How can we prevent medication errors, featuring 10 speakers from 6 countries across the world. Find all the details about the movie along with full interviews with speakers in the movie here: https://www.facesofdigitalhealth.com/overdose-documentary !!! If you are a clinician in the US, you can actually earn CME credits by listening to this show. Find the link to more details in the show notes. The CMEfy process is powered by Adaptrack - a simple platform to unlock precious time & money, while avoiding malpractice, burnout & administrative risks.  CMEfy this topic:  https://earnc.me/SneirH Leave a rating or review for the show: https://lovethepodcast.com/facesofdigitalhealth 

Early in the pandemic, Amazon Web Services (AWS) launched the Diagnostic Development Initiative (DDI) to help organizations around the world accelerate diagnostics research and development. In the first phase of the initiative, AWS awarded $8 million in computing credits and technical support to 87 organizations in 17 countries. Some of the highlights include:   Stanford University School of Medicine's smartwatch app that detects early signs of COVID-19 Ilumina's identification of viral mutations through next-gen sequencing Chan-Zuckerberg Biohub used Machine Learning to estimate the number of unreported COVID-19 Cases University of British Columbia & Vancouver General Hospital applied machine learning to CT scans to identify indicators of COVIOD-19 and detect more severe progression of the disease. Then they open sourced the model.   Today we're talking with Grace Kitzmiller, Principal Product Manager of AWS Disaster Response about the next round of DDI. AWS will distribute an additional $12 million in compute resources and technical support to organizations working in three areas:   Early disease detection Prognosis Public Health Genomics   And while AWS will continue to support COVID-19 projects, they will also consider projects focused on other infectious diseases. The application is open now and runs through the end of the year. However, AWS is encouraging applicants to submit by July 31, 2021, for priority consideration.   In this interview we discuss:   The details of the AWS Diagnostic Development Initiative (DDI). The problems AWS is trying to solve. How AWS is measuring the success of the initiative. The highlights and major outcomes from round 1. How the program is being expanded for round 2. How organizations can apply the compute, technical resources, and subject matter expertise made available through DDI. Who should apply? Plus, we do some brainstorming on possible solutions that could benefit from the program.   This is a great opportunity for organizations to accelerate their work in diagnostics and we encourage you to check it out.   Links and Resources   AWS Activate offers startups free tools, resources, and more to quickly get started on AWS Registry of Open Data on AWS is a registry that exists to help people discover and share datasets that are available via AWS resources. Synthea provides realistic health data at no cost. Check out all our coverage in Infection Prevention and Control Check out our sister podcast TIPS Deep Dive Interviews for discussions with the best minds in global health.     The #HCBiz Show! is produced by Glide Health IT, LLC in partnership with Netspective Media.  Music by StudioEtar

This marks the 150th episode of DNA Today! Our guests to celebrate this landmark episode of DNA Today are Dr. Euan Ashley, a medical geneticist and cardiologist. And Dr. Stephen Quake, a physics professor, bioengineer and pioneer in microfluidics. A Scotland native, Dr. Euan Ashley graduated with degrees in Physiology and Medicine from the University of Glasgow. He completed medical residency and a PhD in molecular physiology at the University of Oxford before moving to Stanford University where he trained in cardiology and advanced heart failure, joining the faculty in 2006. In 2010, he led the team that carried out the first clinical interpretation of a human genome. The paper published in the Lancet was the focus of over 300 news stories, and became one of the most cited articles in clinical medicine that year. The team extended the approach in 2011 to a family of four and now routinely applies genome sequencing to the diagnosis of patients at Stanford hospital where Dr. Ashley directs the Clinical Genome Service and the Center for Inherited Cardiovascular Disease. In 2014, Dr Ashley became co-chair of the steering committee of the NIH Undiagnosed Diseases Network. Stephen Quake is a professor of bioengineering and applied physics at Stanford University and is co-President of the Chan Zuckerberg Biohub. He holds a B.S. in Physics and M.S. in Mathematics from Stanford University and a doctorate in Theoretical Physics from the University of Oxford. Dr. Quake has invented many measurement tools for biology, including new DNA sequencing technologies that have enabled rapid analysis of the human genome and microfluidic automation that allows scientists to efficiently isolate individual cells and decipher their genetic code. Dr. Quake is also well known for inventing new diagnostic tools, including the first non-invasive prenatal test for Down syndrome and other aneuploidies. His test is rapidly replacing risky invasive approaches such as amniocentesis, and millions of women each year now benefit from this approach. He was also the fifth person in the world to have their genome sequences and his genome was the subject of clinical annotation by a large team at Stanford Hospital led by Dr. Ashley. On This Episode We Discuss:The first clinical interpretation of a human genomeGenome sequencing technologiesThe cost of sequencing a genome Understanding the genomic codeThe future of precision medicineDr. Ashley's book, The Genome OdysseyWant to read the Genome Odyssey? Enter to win your own copy! Head over to our Twitter, Instagram, Facebook, and LinkedIn to enter to win a free book!Be sure to follow Dr. Ashley and Dr. Quake on Twitter! How do you keep research articles organized? We have struggled with this for years, but have finally found a solution that is simple and easy. It's called Paperpile! It radically simplifies the workflow of collecting, managing and writing papers. Paperpile allows you to highlight and annotate papers, manage references, share and collaborate and even cite directly in Google Docs and Microsoft Word. Paperpile's new mobile apps allows you to sync your library to all your devices so you can read and annotate on your iPad, iPhone, or Android device. Start your free 30 day trial today at paperpile.com with promo code “DNATODAY”. Paperpile costs only $36 per year, but with code “DNATODAY” you save 20%! Want to become a genetic counselor? Looking for ways to engage with the field and boost your resume for grad school applications? Then you should check out Sarah Lawrence's “Why Genetic Counseling Wednesday Summer Series”! Every Wednesday this June Sarah Lawrence is hosting this series where you can interact through Zoom with genetic counselors from different specialties for an hour and a half. You can sign up at SLC.edu/DNAtoday to register to level up your resume for applications in the fall. Stay tuned for the next new episode of DNA Today on July 2nd, 2021! We'll be joined by Dr. Richard Michelmore and Dr. Brad Pollock who will be discussing COVID-19 variants. New episodes are released on the first and third Friday of the month. In the meantime, you can binge over 150 other episodes on Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “DNA Today”. All episodes in 2021 are also recorded with video which you can watch on our YouTube channel. See what else we are up to on Twitter, Instagram, Facebook, YouTube and our website, DNApodcast.com. Questions/inquiries can be sent to info@DNApodcast.com.

Best-selling author Michael Lewis has a knack for extracting page-turning drama out of otherwise mundane and complicated subjects (hello, bond trading and baseball stats). Several of those books have been so good they’ve been turned into award-winning dramas starring half of Hollywood (hello, “The Big Short” and “Moneyball). And now, Lewis takes a crack at the pandemic realty still unfolding. His new book is called “The Premonition: A Pandemic Story.” In it, Lewis uses the first-hand accounts of three main characters to unravel the government’s gross mismanagement of the COVID response, which lead to nearly 600,000 deaths (among the world’s worst outcomes). On this episode of Next Question with Katie Couric, Katie and Michael Lewis talk about the CDC’s shocking downfall, the gaping holes in the public health system and the secret group of doctors (the so-called “Wolverines) helping to single handedly patch that system together. We also get to hear from one of those doctors, Dr. Joe DeRisi, a biochemistry professor at the University of California, San Francisco, and co-president of the Chan-Zuckerberg Biohub. Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

Hear scientists from the Chan Zuckerberg Biohub and UCSF describe their work providing COVID-19 testing and genomic sequencing of SARS-CoV-2 for California.

In the future data science and artificial intelligence will be routinely used to give clinicians diagnostic recommendations; give scientists testable hypotheses they can confirm experimentally and offer them insights into safe and precise treatments; and give patients guidance on self-care, e.g., how to lead a healthy lifestyle and recognize disease early. Marinka Zitnik, PhD is an Assistant Professor of Biomedical Informatics, Harvard Medical School. Before joining Harvard, Dr. Zitnik was a postdoctoral fellow in Computer Science at Stanford University and was involved in projects at Chan Zuckerberg Biohub. Listen in as David and Marinka explain some AI concepts such as encoding, decoding, and embedding as well as discuss algorithms that can predict drug-drug interactions and identify medications that may be good candidates to treat COVID-19.  See omnystudio.com/listener for privacy information. Learn more about your ad choices. Visit megaphone.fm/adchoices

In the future data science and artificial intelligence will be routinely used to give clinicians diagnostic recommendations; give scientists testable hypotheses they can confirm experimentally and offer them insights into safe and precise treatments; and give patients guidance on self-care, e.g., how to lead a healthy lifestyle and recognize disease early. Marinka Zitnik, PhD is an Assistant Professor of Biomedical Informatics, Harvard Medical School. Before joining Harvard, Dr. Zitnik was a postdoctoral fellow in Computer Science at Stanford University and was involved in projects at Chan Zuckerberg Biohub. Listen in as David and Marinka explain some AI concepts such as encoding, decoding, and embedding as well as discuss algorithms that can predict drug-drug interactions and identify medications that may be good candidates to treat COVID-19.  See omnystudio.com/listener for privacy information.

In the future data science and artificial intelligence will be routinely used to give clinicians diagnostic recommendations; give scientists testable hypotheses they can confirm experimentally and offer them insights into safe and precise treatments; and give patients guidance on self-care, e.g., how to lead a healthy lifestyle and recognize disease early. Marinka Zitnik, PhD is an Assistant Professor of Biomedical Informatics, Harvard Medical School. Before joining Harvard, Dr. Zitnik was a postdoctoral fellow in Computer Science at Stanford University and was involved in projects at Chan Zuckerberg Biohub. Listen in as David and Marinka explain some AI concepts such as encoding, decoding, and embedding as well as discuss algorithms that can predict drug-drug interactions and identify medications that may be good candidates to treat COVID-19.  See omnystudio.com/listener for privacy information.

Hear scientists from the Chan Zuckerberg Biohub and UCSF describe their work providing COVID-19 testing and genomic sequencing of SARS-CoV-2 for California.

My guest this week is Dr. Joe DeRisi, a pioneer in functional genomics and leader of a collaborative effort to accelerate SARS-CoV-2 testing and discovery. Joe is the co-President of the Chan Zuckerberg Biohub and has had a remarkable series of technological breakthroughs throughout his career, including the invention of DNA microarrays. He talks about applying these approaches to diagnose mysterious diseases in humans and pets as well as his current focus on COVID-19.

Pogovarjal sem se z Nino in dr. Juretom Leskovec. Nina je magistra kvantitativnih financ, sedaj zaposlena na podjetju ComCom, kjer se ukvarja s podatkovno analitiko ter direktorica ASEF Slovenije. Jure je profesor na univerzi Stanford v San Franciscu, glavni znanstvenik na podjetju Pinterest ter raziskovalec na inštitutu Chan Zuckerberg Biohub. Jure je leta 2014 soustanovil fundacijo ASEF. ASEF je ameriško-slovenska izobraževalna fundacija, ki spodbuja kroženje znanja in povezuje slovenske izobražence in profesorje po celem svetu, zakar so leta 2018 prejeli priznanje VTIS leta. V fundaciji je zbranih preko 50 svetovno priznanih slovenskih profesorjev, ki delujejo na najboljših univerzah po svetu. Preko fundacije sodelujejo s Slovenijo ter mlad in v Sloveniji omogočajo rast in razvoj. V teh letih je ASEF s štipendijami in programi pomagal preko 130 mladim.

Welcome to The Scientist's LabTalk, a special edition podcast produced by The Scientist's Creative Services Team where we explore topics at the leading edge of innovative research.  In this episode, we explore how neurons withstand stress by looking at three cutting edge technologies: CRISPR, stem cell technology, and single-cell sequencing. Tiffany Garbutt from The Scientist's Creative Services team spoke with Martin Kampmann, associate professor at the University of California San Francisco, Chan Zuckerberg Biohub investigator, and Paul G. Allen Distinguished Investigator to learn more. This episode is brought to you by 10x Genomics. 10x Genomics builds solutions for interrogating biological systems at a resolution and scale that matches the complexity of biology. Their rapidly expanding suite of products, which includes instruments, consumables, and software, enables customers to make fundamental discoveries across multiple research areas, including cancer, immunology, and neuroscience.

On the exact 6-month anniversary of San Francisco's shelter-in-place ordnance, UCSF infectious disease experts look back at what we've learned about the strengths and weaknesses of our public health systems and look forward to the next stage of the fight against COVID-19. Panelists will discuss how the pandemic has taken advantage of inequities in our society to continue spreading despite the region's early response—and the growing understanding that stemming the tide of COVID-19 will require much greater support for low-income essential workers, incarcerated populations, and others least able to protect themselves. They will explore how partnerships between community leaders, UCSF scientists, and public health officials are pointing the way forward to a more just, equitable and effective response to the pandemic. Meet the panelists: Joe DeRisi, Ph.D., is Tomkins Professor in the Department of Biochemistry at UCSF and co-director of the Chan Zuckerberg Biohub, an independent research institute dedicated to eradicating disease. DeRisi has a long history as a “virus detective” and inventor. During the severe testing backlog at the start of the pandemic, his team built a state-of-the-art COVID-19 testing center in 8 days, which soon became the hub for processing test kits from public health departments across the state. Diane Havlir, M.D., is chief of the UCSF Division of HIV, Infectious Disease and Global Medicine. At the start of the pandemic, Havlir—who is a veteran of the fight against AIDS—joined forces with Latinx community leaders such as Jon Jacobo of the Latino Task Force for COVID-19, to document inequalities in the pandemic's impact on low-income workers and their families, and to link those infected with the support they need to go into isolation. This “test-to-care” approach has become a model for similar efforts across the country. Jon Jacobo, of the Latino Task Force for COVID-19, helped spearhead the group's partnership with UCSF, called Unidos En Salud, and has worked for policy changes to support low-income essential workers during the pandemic, in partnership with the City and County of San Francisco Department of Public Health. Jacobo is director of engagement and policy for TODCO Group, a San Francisco affordable housing and advocacy nonprofit, and an appointed commissioner overseeing the San Francisco Department of Building Inspection. Brie Williams, M.D., M.S., is a professor in the UCSF Division of Geriatrics and founding director of UCSF Amend, an initiative dedicated to transforming correctional culture to improve the health of people living and working in America's prisons. Her research has pushed for changes in how California's prisons have handled outbreaks during the pandemic, not only to protect prisoners and prison workers, but to prevent spill-over into the community at large. Moderator Kirsten Bibbins-Domingo, Ph.D., M.D., M.A.S., is vice dean for population health and health equity at the UCSF School of Medicine and director of the UCSF COVID-19 Community Public Health Initiative. She has written about how the pandemic has created “two Californias”—those with the privilege of sheltering in place, and the low-income workers who have been forced to choose between keeping food on the table and protecting their families from the virus In association with UCSF Learn more about your ad choices. Visit megaphone.fm/adchoices

Nikki Teran interviews Stanford Medicine Professor, Dr. Bonnie Maldonado, on the societal factors that lead to health inequality. Dr. Maldonado discusses her projects with the Chan Zuckerberg Initiative to learn more about the spread of COVID-19 and gather more socially equitable health data. For more details on the nine-month research collaboration across the Bay Area between Stanford, UCSF and Chan Zuckerberg Biohub, follow here. Recorded on June 4, 2020.

In this new episode, launched on World AIDS Day 2019, we meet Cristina Tato, Associate Director of the CZ Biohub Infectious Disease Rapid Response Team, and explore the lessons learned from the AIDS epidemic, and how societies need to prepare for new outbreaks.---A Shot in the Arm Podcast Webpage - http://www.ashotinthearmpodcast.comFacebook: @shotarmpodcast - http://bit.ly/asita_fbvideosYouTube: @shotarmpodcast - http://bit.ly/asita_youtubeApple Podcasts - http://bit.ly/asita_appleGoogle Podcasts - http://bit.ly/asita_googleSpotify - http://bit.ly/asita_spotifyiHeart Radio - http://bit.ly/asita_iheartStitcher - http://bit.ly/asita_stitcherTuneIn (and Alexa enabled devices) - http://bit.ly/asita_tuneinRSS Feed - https://feeds.buzzsprout.com/276933.rss

Genomics-based technologies have revolutionized science. From microarrays to next-generation sequencing, genomics technologies are having a tremendous positive impact on all aspects of human health. Dr. Joe DeRisi is a professor at the University of California San Francisco and co-president of the Chan Zuckerberg Biohub. DeRisi has been at the forefront of developing and using genomics-based technologies to address infectious disease challenges. DeRisi talks about how genomics helped solve the mystery of dying leopard sharks in San Francisco bay, how a “virochip” array helped identify the SARS virus, how genomics can help identify unknown causes of encephalitis, how the sewer may hold the key to predicting infectious disease outbreaks, how computational capabilities represent the current bottleneck to global benefit from genomics technologies, and how the early mysteries surrounding the AIDS epidemic led him into science. microTalk was thrilled to be joined by Julie Wolf, “Meet the Microbiologist” podcast host from ASM, when this podcast was recorded at the ASM Microbe 2019 conference in San Francisco, CA. The microCase for listeners to solve is about Tess Tamoni, a retired teacher who gets a nasty infection while on vacation at a tropical resort. Participants: Karl Klose, Ph.D. (UTSA) Joe DeRisi, Ph.D. (University of California San Francisco) Janakiram Seshu, Ph.D. (UTSA) Mylea Echazarreta (UTSA) Julie Wolf (ASM)

Mark sits down with Dr. Joe DeRisi and Dr. Stephen Quake, who lead the Chan Zuckerberg Biohub, a nonprofit research center that brings together scientists and engineers from Stanford, Berkeley, and UCSF. They talk about how technology is accelerating health research, the new advancements they’re most excited about, how to restore faith in science and what wearables will mean for the future of health.

Joseph DeRisi describes the Chan Zuckerberg Biohub, a new privately-funded medical research center in the Bay Area.

In Talking Precision Medicine podcast we sit down with experts on the application of AI and big data analytics in the drug discovery space. Our guests are innovators, business decision makers and thought leaders at the intersection of data and therapeutics. We discuss the promise, practice, challenges, and myths of AI in precision medicine. This show is brought to you by Genialis, and Rafael, our CEO, is your host. Genialis is focused on data integration and predictive modeling of disease biology to help accelerate the discovery and de-risk the development of novel therapeutics. Today we speak with Dr. Nicole Paulk. Nicole is an assistant professor at the University of California San Francisco, and the Advisory Lead for Genome Engineering at Chan Zuckerberg Biohub. Nicole’s lab builds technologies to advance the entire field of viral gene therapy. They are a force behind the rising tide lifting the gene therapy industry. She is also committed to training the next generation of scientist innovators.

It is not news that UC Berkeley is under continual financial pressure due to a challenging mix of increased enrollment, insufficient state funding and a tuition freeze. But by July 2019 Berkeley is expected to return to a balanced budget and financial health, and Chancellor Carol Christ is already looking to the future. Hear her discuss a new vision for undergraduate education that goes beyond the completion of assignments to immersion in the discovery and the creation of knowledge. Christ's signature Initiatives include: translating UCB's research into inventions, governmental policies and services that advance the greater good; emphasizing research initiatives like Chan Zuckerberg Biohub, which span the old dividing lines between disciplines, departments and even institutions; supporting the exploding interest in data science across the full range of academic disciplines; implementing a new free speech policy that sustains a commitment to the First Amendment while supporting the campus community's values and protecting Berkeley's actual operations from unnecessary disruption; and promoting diversity as an essential element for a campus that seeks to embody and represent California and that needs to prepare students to succeed in a multicultural world. MLF ORGANIZER NAME George Hammond NOTES MLF: Humanities Learn more about your ad choices. Visit megaphone.fm/adchoices

Guest: Alex Marson Age: 39 years Location: San Francisco Bio: The Marson lab at UCSF is developing CRISPR engineering technologies to reprogram human immune cells to create a new class of treatments for cancer, autoimmune diseases, and infectious diseases. Alex Marson completed medical school at Harvard, Ph.D. training at the Whitehead Institute/MIT, Internal Medicine residency at the Brigham and Women’s and clinical training in Infectious Diseases at UCSF. Marson received the prestigious UCSF Sandler Faculty Fellowship, which offered him an accelerated path to start his own lab. Marson is now an associate professor in the UCSF Department of Microbiology and Immunology, with joint appointments in the Department of Medicine and the Diabetes Center. He is also affiliated with the UCSF Helen Diller Cancer Center. He is the scientific director of biomedicine at the Innovative Genomics Institute (IGI) and was selected as one of the inaugural Chan Zuckerberg Biohub investigators. His lab integrates systems-scale investigations of human T cell circuitry with functional perturbation studies, including genome editing in primary T cells. The World Needs More: 1. Connection -- a shared sense of meaning and purpose. Where there is connection there is hope!  Wow Factor: Tune in and find out!  Favorite Color: TBD

Simon shares a great list of new capabilities for customers! Chapters: 00:00- 00:08 Opening 00:09 - 10:50 Compute 10:51 - 25:50 Database and Storage 25:51 - 28:25 Network 28:26 - 35:01 Development 35:09 - 39:03 AI/ML 39:04 - 45:04 System Management and Operations 45:05 - 46:18 Identity 46:19 - 48:05 Video Streaming 48:06 - 49:14 Public Datasets 49:15 - 49:54 AWS Marketplace 49:55 - 51:03 YubiKey Support for MFA 51:04 - 51:18 Closing Shownotes: Amazon EC2 F1 Instance Expands to More Regions, Adds New Features, and Improves Development Tools | https://aws.amazon.com/about-aws/whats-new/2018/10/amazon-ec2-f1-instance-expands-to-more-regions-adds-new-features-and-improves-development-tools/ Amazon EC2 F1 instances now Available in an Additional Size | https://aws.amazon.com/about-aws/whats-new/2018/09/amazon-ec2-f1-instances-now-available-in-an-additional-size/ Amazon EC2 R5 and R5D instances now Available in 8 Additional AWS Regions | https://aws.amazon.com/about-aws/whats-new/2018/09/amazon-ec2-r5-and-r5d-instances-now-available-in-8-additional-aws-regions/ Introducing Amazon EC2 High Memory Instances with up to 12 TB of memory, Purpose-built to Run Large In-memory Databases, like SAP HANA | https://aws.amazon.com/about-aws/whats-new/2018/09/introducing-amazon-ec2-high-memory-instances-purpose-built-to-run-large-in-memory-databases/ Introducing a New Size for Amazon EC2 G3 Graphics Accelerated Instances | https://aws.amazon.com/about-aws/whats-new/2018/10/introducing-a-new-size-for-amazon-ec2-g3-graphics-accelerated-instances/ Amazon EC2 Spot Console Now Supports Scheduled Scaling for Application Auto Scaling | https://aws.amazon.com/about-aws/whats-new/2018/09/amazon-ec2-spot-console-now-supports-scheduled-scaling-for-application-auto-scaling/ Amazon Linux 2 Now Supports 32-bit Applications and Libraries | https://aws.amazon.com/about-aws/whats-new/2018/09/amazon-linux-2-now-supports-32-bit-applications-and-libraries/ AWS Server Migration Service Adds Support for Migrating Larger Data Volumes | https://aws.amazon.com/about-aws/whats-new/2018/09/aws-server-migration-service-adds-support-for-migrating-larger-data-volumes/ AWS Migration Hub Saves Time Migrating with Application Migration Status Automation | https://aws.amazon.com/about-aws/whats-new/2018/10/aws_migration_hub_saves_time_migrating_with_application_migration_status_automation/ Plan Your Migration with AWS Application Discovery Service Data Exploration | https://aws.amazon.com/about-aws/whats-new/2018/09/plan-your-migration-with-aws-application-discovery-service-data-exploration/ AWS Lambda enables functions that can run up to 15 minutes | https://aws.amazon.com/about-aws/whats-new/2018/10/aws-lambda-supports-functions-that-can-run-up-to-15-minutes/ AWS Lambda announces service level agreement | https://aws.amazon.com/about-aws/whats-new/2018/10/aws-lambda-introduces-service-level-agreement/ AWS Lambda Console Now Enables You to Manage and Monitor Serverless Applications | https://aws.amazon.com/about-aws/whats-new/2018/08/aws-lambda-console-enables-managing-and-monitoring/ Amazon EKS Enables Support for Kubernetes Dynamic Admission Controllers | https://aws.amazon.com/about-aws/whats-new/2018/10/amazon-eks-enables-support-for-kubernetes-dynamic-admission-cont/ Amazon EKS Simplifies Cluster Setup with update-kubeconfig CLI Command | https://aws.amazon.com/about-aws/whats-new/2018/09/amazon-eks-simplifies-cluster-setup-with-update-kubeconfig-cli-command/ Amazon Aurora Parallel Query is Generally Available | https://aws.amazon.com/about-aws/whats-new/2018/09/amazon-aurora-parallel-query-is-generally-available/ Amazon Aurora Now Supports Stopping and Starting of Database Clusters | https://aws.amazon.com/about-aws/whats-new/2018/09/amazon-aurora-stop-and-start/ Amazon Aurora Databases Support up to Five Cross-Region Read Replicas | https://aws.amazon.com/about-aws/whats-new/2018/09/amazon-aurora-databases-support-up-to-five-cross-region-read-replicas/ Amazon RDS Now Provides Database Deletion Protection | https://aws.amazon.com/about-aws/whats-new/2018/09/amazon-rds-now-provides-database-deletion-protection/ Announcing Managed Databases for Amazon Lightsail | https://aws.amazon.com/about-aws/whats-new/2018/10/announcing-managed-databases-for-amazon-lightsail/ Amazon RDS for MySQL and MariaDB now Support M5 Instance Types | https://aws.amazon.com/about-aws/whats-new/2018/09/amazon-rds-for-mysql-and-mariadb-support-m5-instance-types/ Amazon RDS for Oracle Now Supports Database Storage Size up to 32TiB | https://aws.amazon.com/about-aws/whats-new/2018/10/amazon-rds-for-oracle-now-supports-32tib/ Specify Parameter Groups when Restoring Amazon RDS Backups | https://aws.amazon.com/about-aws/whats-new/2018/10/specify-parameter-groups-when-restoring-amazon-rds-backups/ Amazon ElastiCache for Redis adds read replica scaling for Redis Cluster | https://aws.amazon.com/about-aws/whats-new/2018/09/amazon-elasticache-for-redis-adds-read-replica-scaling-for-redis-cluster/ Amazon Elasticsearch Service now supports encrypted communication between Elasticsearch nodes | https://aws.amazon.com/about-aws/whats-new/2018/09/amazon_elasticsearch_service_now_supports_encrypted_communication_between_elasticsearch_nodes/ Amazon Athena adds support for Creating Tables using the results of a Select query (CTAS) | https://aws.amazon.com/about-aws/whats-new/2018/10/athena_ctas_support/ Amazon Redshift announces Query Editor to run queries directly from the AWS Management Console | https://aws.amazon.com/about-aws/whats-new/2018/10/amazon_redshift_announces_query_editor_to_run_queries_directly_from_the_aws_console/ Support for TensorFlow and S3 select with Spark on Amazon EMR release 5.17.0 | https://aws.amazon.com/about-aws/whats-new/2018/09/support-for-tensorflow-s3-select-with-spark-on-amazon-emr-release-517/ AWS Database Migration Service Makes It Easier to Migrate Cassandra Databases to Amazon DynamoDB | https://aws.amazon.com/about-aws/whats-new/2018/09/aws-dms-aws-sct-now-support-the-migration-of-apache-cassandra-databases/ The Data Lake Solution Now Integrates with Microsoft Active Directory | https://aws.amazon.com/about-aws/whats-new/2018/09/the-data-lake-solution-now-integrates-with-microsoft-active-directory/ Amazon S3 Announces Selective Cross-Region Replication Based on Object Tags | https://aws.amazon.com/about-aws/whats-new/2018/09/amazon-s3-announces-selective-crr-based-on-object-tags/ AWS Storage Gateway Is Now Available as a Hardware Appliance | https://aws.amazon.com/about-aws/whats-new/2018/09/aws-storage-gateway-is-now-available-as-a-hardware-appliance/ AWS PrivateLink now supports access over AWS VPN | https://aws.amazon.com/about-aws/whats-new/2018/09/aws-privatelink-now-supports-access-over-aws-vpn/ AWS PrivateLink now supports access over Inter-Region VPC Peering | https://aws.amazon.com/about-aws/whats-new/2018/10/aws-privatelink-now-supports-access-over-inter-region-vpc-peering/ Network Load Balancer now supports AWS VPN | https://aws.amazon.com/about-aws/whats-new/2018/09/network-load-balancer-now-supports-aws-vpn/ Network Load Balancer now supports Inter-Region VPC Peering | https://aws.amazon.com/about-aws/whats-new/2018/10/network-load-balancer-now-supports-inter-region-vpc-peering/ AWS Direct Connect now Supports Jumbo Frames for Amazon Virtual Private Cloud Traffic | https://aws.amazon.com/about-aws/whats-new/2018/10/aws-direct-connect-now-supports-jumbo-frames-for-amazon-virtual-private-cloud-traffic/ Amazon CloudFront announces two new Edge locations, including its second location in Fujairah, United Arab Emirates | https://aws.amazon.com/about-aws/whats-new/2018/10/cloudfront-fujairah/ AWS CodeBuild Now Supports Building Bitbucket Pull Requests | https://aws.amazon.com/about-aws/whats-new/2018/10/aws-codebuild-now-supports-building-bitbucket-pull-requests/ AWS CodeCommit Supports New File and Folder Actions via the CLI and SDKs | https://aws.amazon.com/about-aws/whats-new/2018/09/aws-codecommit-supports-new-file-and-folder-actions-via-the-cli-and-sdks/ AWS Cloud9 Now Supports TypeScript | https://aws.amazon.com/about-aws/whats-new/2018/10/aws-cloud9-now-supports-typescript/ AWS CloudFormation coverage updates for Amazon API Gateway, Amazon ECS, Amazon Aurora Serverless, Amazon ElastiCache, and more | https://aws.amazon.com/about-aws/whats-new/2018/09/aws-cloudformation-coverage-updates-for-amazon-api-gateway--amaz/ AWS Elastic Beanstalk adds support for T3 instance and Go 1.11 | https://aws.amazon.com/about-aws/whats-new/2018/09/aws-elastic-beanstalk-adds-support-for-t3-instance-and-go-1-11/ AWS Elastic Beanstalk Console Supports Network Load Balancer | https://aws.amazon.com/about-aws/whats-new/2018/10/aws_elastic_beanstalk_console_supports_network_load_balancer/ AWS Amplify Announces Vue.js Support for Building Cloud-powered Web Applications | https://aws.amazon.com/about-aws/whats-new/2018/09/aws-amplify-announces-vuejs-support-for-building-cloud-powered-web-applications/ AWS Amplify Adds Support for Securely Embedding Amazon Sumerian AR/VR Scenes in Web Applications | https://aws.amazon.com/about-aws/whats-new/2018/09/AWS-Amplify-adds-support-for-securely-embedding-Amazon-Sumerian/ Amazon API Gateway adds support for multi-value parameters | https://aws.amazon.com/about-aws/whats-new/2018/10/amazon-api-gateway-adds-support-for-multi-parameters/ Amazon API Gateway adds support for OpenAPI 3.0 API specification | https://aws.amazon.com/about-aws/whats-new/2018/09/amazon-api-gateway-adds-support-for-openapi-3-api-specification/ AWS AppSync Launches a Guided API Builder for Mobile and Web Apps | https://aws.amazon.com/about-aws/whats-new/2018/09/AWS-AppSync-launches-a-guided-API-builder-for-apps/ Amazon Polly Adds Mandarin Chinese Language Support | https://aws.amazon.com/about-aws/whats-new/2018/09/amazon-polly-adds-mandarin-chinese-language-support/ Amazon Comprehend Extends Natural Language Processing for Additional Languages and Region | https://aws.amazon.com/about-aws/whats-new/2018/10/amazon_comprehend_extends_natural_language_processing_for_additional_languages_and_region/ Amazon Transcribe Supports Deletion of Completed Transcription Jobs | https://aws.amazon.com/about-aws/whats-new/2018/10/amazon_transcribe_supports_deletion_of_completed_transcription_jobs/ Amazon Rekognition improves the accuracy of image moderation | https://aws.amazon.com/about-aws/whats-new/2018/10/amazon-rekognition-improves-the-accuracy-of-image-moderation/ Save time and money by filtering faces during indexing with Amazon Rekognition | https://aws.amazon.com/about-aws/whats-new/2018/09/save-time-and-money-by-filtering-faces-during-indexing-with-amazon-rekognition/ Amazon SageMaker Now Supports Tagging for Hyperparameter Tuning Jobs | https://aws.amazon.com/about-aws/whats-new/2018/09/amazon-sagemaker-now-supports-tagging-for-hyperparameter-tuning-/ Amazon SageMaker Now Supports an Improved Pipe Mode Implementation | https://aws.amazon.com/about-aws/whats-new/2018/10/amazon-sagemaker-now-supports-an-improved-pipe-mode-implementati/ Amazon SageMaker Announces Enhancements to its Built-In Image Classification Algorithm | https://aws.amazon.com/about-aws/whats-new/2018/10/amazon-sagemaker-announces-enhancements-to-its-built-in-image-cl/ AWS Glue now supports connecting Amazon SageMaker notebooks to development endpoints | https://aws.amazon.com/about-aws/whats-new/2018/10/aws-glue-now-supports-connecting-amazon-sagemaker-notebooks-to-development-endpoints/ AWS Glue now supports resource-based policies and resource-level permissions for the AWS Glue Data Catalog | https://aws.amazon.com/about-aws/whats-new/2018/10/aws-glue-now-supports-resource-based-policies-and-resource-level-permissions-and-for-the-AWS-Glue-Data-Catalog/ Resource Groups Tagging API Supports Additional AWS Services | https://aws.amazon.com/about-aws/whats-new/2018/10/resource-groups-tagging-api-supports-additional-aws-services/ Changes to Tags on AWS Resources Now Generate Amazon CloudWatch Events | https://aws.amazon.com/about-aws/whats-new/2018/09/changes-to-tags-on-aws-resources-now-generate-amazon-cloudwatch-events/ AWS Systems Manager Announces Enhanced Compliance Dashboard | https://aws.amazon.com/about-aws/whats-new/2018/10/aws-systems-manager-announces-enhanced-compliance-dashboard/ Conditional Branching Now Supported in AWS Systems Manager Automation | https://aws.amazon.com/about-aws/whats-new/2018/09/Conditional_Branching_Now_Supported_in_AWS_Systems_Manager_Automation/ AWS Systems Manager Launches Custom Approvals for Patching | https://aws.amazon.com/about-aws/whats-new/2018/10/AWS_Systems_Manager_Launches_Custom_Approvals_for_Patching/ Amazon CloudWatch adds Ability to Build Custom Dashboards Outside the AWS Console | https://aws.amazon.com/about-aws/whats-new/2018/09/amazon-cloudwatch-adds-ability-to-build-custom-dashboards-outside-the-aws-console/ Amazon CloudWatch Agent adds Custom Metrics Support | https://aws.amazon.com/about-aws/whats-new/2018/09/amazon-cloudwatch-agent-adds-custom-metrics-support/ Amazon CloudWatch Launches Client-side Metric Data Aggregations | https://aws.amazon.com/about-aws/whats-new/2018/10/amazon-cloudWatch-launches-client-side-metric-data-aggregations/ AWS IoT Device Management Now Provides In Progress Timeouts and Step Timeouts for Jobs | https://aws.amazon.com/about-aws/whats-new/2018/10/aws-iot-device-management-now-provides-in-progress-timeouts-and-step-timeouts-for-jobs/ Amazon GuardDuty Provides Customization of Notification Frequency to Amazon CloudWatch Events | https://aws.amazon.com/about-aws/whats-new/2018/10/amazon-guardduty-provides-customization-of-notification-frequency-to-amazon-cloudwatch-events/ AWS Managed Microsoft AD Now Offers Additional Configurations to Connect to Your Existing Microsoft AD | https://aws.amazon.com/about-aws/whats-new/2018/10/aws-managed-microsoft-ad-now-offers-additional-configurations-to-connect-to-our-existing-microsoft-ad/ Easily Deploy Directory-Aware Workloads in Multiple AWS Accounts and VPCs by Sharing a Single AWS Managed Microsoft AD | https://aws.amazon.com/about-aws/whats-new/2018/09/aws-directory-service-share-directory-across-accounts-and-vpcs/ AWS Single Sign-on Now Enables You to Customize the User Experience to Business Applications | https://aws.amazon.com/about-aws/whats-new/2018/10/aws-single-sign-on-now-enables-you-to-customize-the-user-experience-to-business-applications/ Live Streaming on AWS Now Features AWS Elemental MediaLive and MediaPackage | https://aws.amazon.com/about-aws/whats-new/2018/09/live-streaming-on-aws-now-features-aws-elemental-medialive-and-mediapackage/ AWS Elemental MediaStore Increases Object Size Limit to 25 Megabytes | https://aws.amazon.com/about-aws/whats-new/2018/10/aws-elemental-mediastore-increase-object-size-limit-to-25-megabytes/ Amazon Kinesis Video Streams now supports adding and retrieving Metadata at Fragment-Level | https://aws.amazon.com/about-aws/whats-new/2018/10/kinesis-video-streams-fragment-level-metadata-support/ AWS Public Datasets Now Available from the German Meteorological Office, Broad Institute, Chan Zuckerberg Biohub, fast.ai, and Others | https://aws.amazon.com/about-aws/whats-new/2018/10/public-datasets/ Customize Your Payment Frequency and More with AWS Marketplace Flexible Payment Scheduler | https://aws.amazon.com/about-aws/whats-new/2018/10/customize-your-payment-frequency-and-more-with-awsmarketplace-flexible-payment-scheduler/ Sign in to your AWS Management Console with YubiKey Security Key for Multi-factor Authentication (MFA) | https://aws.amazon.com/about-aws/whats-new/2018/09/aws_sign_in_support_for_yubikey_security_key_as_mfa/

Jure Leskovec is the Chief Scientist of Pinterest, an $11 billion dollar company hosting over 75 billion idea “pins” from it’s 175 million monthly users worldwide. Jure originally arrived at Pinterest in 2014 when his company, Kosei, was acquired after starting a “recommendation revolution” through smarter, personalized mobile ads.  When Jure is not “turning cameras into keyboards” at Pinterest -- Fast Company’s “2nd most innovative AI company” -- he can also be found fulfilling his responsibilities as a: Associate Professor of Computer Science at Stanford University - where his research focuses on mining and modeling large social and information networks, including relationship graphs and chain effects in online community settings Investigator at the Chan-Zuckerberg Biohub - a multidisciplinary research organization on a mission to make all diseases preventable, manageable or curable by the year 2100 Some favorite topics we covered include: How being Pinterest’s Chief Data Scientist has affected his own social media use The story behind how he went from party conversation about Kosei to company acquisition by Pinterest in just 2 months How Pinterest makes recommendations to it’s users and thinks about the explore vs. exploit tradeoff of social media ads Moral considerations of echo chambers/filter bubbles/confirmation bias that he and his team take into account when serving Pinterest’s 200+ million users content each day Balancing short and long-term benefits at the individual (value to user), community (health of the content ecosystem), & company (ad revenue) level Recent research from Harvard, Stanford, UChicago, & Cornell investigating how machine learning can help criminal court judges make high-stake decisions This turned out to be one of my most fascinating conversations yet, so I hope you enjoy it as much as I did! Show Notes: https://ajgoldstein.com/podcast/ep10/ Jure’s Twitter: https://twitter.com/jure?lang=en AJ’s Twitter: https://twitter.com/ajgoldstein393/

Joseph DeRisi describes the Chan Zuckerberg Biohub, a new privately-funded medical research center in the Bay Area.

How do you balance the fact that your happiness shouldn't be totally dependent on the outcome of your research with the fact that of course it is? Kayla and Sally tackle this listener question, and things get real. Conclusion: getting great results feels great, but if this is your only source of warm fuzzies, you're in trouble. But good friends and experience will get you through (probably). Also, the Chan Zuckerberg Biohub is applying major Silicon Valley thinking - and money - to solve real problems. Yay! But is curing all diseases an excessively lofty goal, or is just the kind of attention that science funding needs? We discuss... Email us - doubleshelixpodcast@gmail.com. Listener Better Talk Next time stories coming soon, so submit yours anonymously today! Twitter - @doubleshelixpod Instagram - @doubleshelixpodcast More: doubleshelix.com & betapleatedchic.com Help spread the love - review us on iTunes!

Stephen Quake is a professor in the department of bioengineering at Stanford University and a serial founder of biotech companies. His talk with Nature Biotechnology covers launching Fluidigm, being chosen as copresident of the Chan Zuckerberg Biohub, and what it was like to be one of the first people to have their genome sequenced. See acast.com/privacy for privacy and opt-out information.